

RECEIVED  
CENTRAL FAX CENTER

JUL 08 2008

Amendments to the Specification

Please replace the paragraph at lines 3-17 of page 28 with the following:

Numerous compounds are described in the literature as having activity against one or more of the biomarkers described herein, and therefore may be evaluated in a sepsis model according to the invention. Examples of such compounds against various targets include, e.g.: Published Patent Application No. US 2004/0209929 (PPAR agonists); Published Patent Application No. US 2004/0186166 (Peroxisome Proliferator Activated Nuclear Receptor Gamma (PPAR $\gamma$ ) activators); Published Patent Application No. US 2004/0162354 (PPAR $\gamma$  agonists); U.S. Patent No. 6,670,364 (MCP-1 antagonists); Published Patent Application No. US 2004/0186143 (modulators of chemokine receptor or MCP-1 activity); Published Patent Application No. US 2004/0198719 (MCP-1 antagonists); Published Patent Application No. US 2004/0151721 (CCR2 antibodies, etc.); Published Patent Application No. US 2004/0186140 (modulators of MCP-1 function); Published Patent Application No. US 2004/0198719 (MCP-1 antagonists); and Published Patent Application No. US 2004/0171551~~2004/0171552~~ (MCP-1 ligands). Additionally, antibodies against such targets may also be tested, such as anti-VEGF antibodies or anti-MCP-1 antibodies (see, e.g., U.S. Provisional Application No. 60/584,365, the disclosure of which is incorporated by reference herein, upon which US 2006/0039913 bases priority).

Replace the second full paragraph on page 44 with the following:

The statistical analyses and figures, unless indicated otherwise, were produced using the statistical software available from the R Project For Statistical Computing at <http://www.r-project.org> (see Ihaka et al., 1996, *Journal of Computational and Graphical Statistics*) and Insightful S-plus® software (<http://www.insightful.com/products/splus/default.asp>).